Higher mortality rates were detected in patients who were positive for anti-MDA5 IgG1 and IgG4, thus suggesting that these two IgG subtypes might serve as useful biomarkers for predicting mortality in patients with DM-ILD (74). This evidence concerns the gene IFIH1 and dermatomyositis.